Posted by Michael Wonder on 25 Jun 2024
Sellas announces US FDA rare paediatric disease designation granted to SLS009 for the treatment of paediatric acute lymphoblastic leukaemia
24 June 2024 - Sellas Life Sciences today announced that the US FDA has granted rare paediatric disease designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of paediatric acute lymphoblastic leukaemia.
Rare paediatric disease designation is granted by the FDA for serious or life-threatening diseases that affect fewer than 200,000 people in the US, and in which the serious or life-threatening manifestations primarily affect individuals less than 18 years of age.
